Chimerix antiviral drug fails, shares plummet to record low

(Reuters) - Chimerix Inc said its oral antiviral drug did not significantly reduce a certain kind of infection in stem cell transplant patients in a late-stage study, sending its shares to a record low.

http://ift.tt/1TnIsYE

from Reuters: Health News
via animenewspro